Vor Biopharma Inc.
For the period ended Dec 31, 2025. Filed Mar 30, 2026.
View on SEC.govAbout this filing
A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.
FY2025 · Filed Mar 30, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Item 16. Form 10-K Summary
None.
SIGNAT URES
Pursuant to the requirements of Section 13 or 15(d) of the Securities Exchange Act of 1934, as amended, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.
| VOR BIOPHARMA INC. | ||
| Date: March 30, 2026 | By: | /s/ Jean-Paul Kress |
|---|---|---|
| Jean-Paul Kress, M.D. | ||
| President, Chief Executive Officer and Chairman | ||
Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, this Report has been signed below by the following persons on behalf of the Registrant in the capacities and on the dates indicated.
| Name | Title | Date |
|---|---|---|
| /s/ Jean-Paul Kress | President, Chief Executive Officer and Chairman (Principal Executive Officer) | March 30, 2026 |
| Jean-Paul Kress, M.D. | ||
| /s/ Sandesh Mahatme | Chief Financial Officer (Principal Financial Officerand Principal Accounting Officer) | March 30, 2026 |
| Sandesh Mahatme | ||
| /s/ Daniella Beckman | Lead Independent Director | March 30, 2026 |
| Daniella Beckman | ||
| /s/ Alexander Cumbo | Director | March 30, 2026 |
| Alexander Cumbo | ||
| /s/ Erez Kalir | Director | March 30, 2026 |
| Erez Kalir | ||
| /s/ Michel Detheux | Director | March 30, 2026 |
| Michel Detheux, Ph.D. | ||
| /s/ Wouter Joustra | Director | March 30, 2026 |
| Wouter Joustra | ||
| /s/ Fouad Namouni | Director | March 30, 2026 |
| Fouad Namouni, M.D. | ||
| /s/ Andrew Levin | Director | March 30, 2026 |
|---|---|---|
| Andrew Levin, M.D., Ph.D. | ||
INDEX TO FINANCIAL STATEMENTS
| Report of Independent Registered Public Accounting Firm (PCAOB ID: 42) | F-1 |
|---|---|
| Consolidated Balance Sheets | F-2 |
| Consolidated Statements of Operations and Comprehensive Loss | F-3 |
| Consolidated Statements of Stockholders’ Equity (Deficit) | F-4 |
| Consolidated Statements of Cash Flows | F-5 |
| Notes to Consolidated Financial Statements | F-7 |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.